Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients

Reuters

2025/10/30

<a href="https://laohu8.com/S/TECX">Tectonic Therapeutic</a> Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients

Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579138473"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579138473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579138473?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579138473","market":"us","top_or_hot":-1,"title":"Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECX","symbol_name":"Tectonic Therapeutic, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL9GFJbv:1","article_id":"2579138473","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579138473","pubTimestamp":1761768078,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction . The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction , with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECX":"Tectonic Therapeutic, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Tectonic Therapeutic报告TX45在PH-HFrEF患者中的阳性1b期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECX":0.9,"NDAQ":0.9},"content_text":"Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n    \n\n        Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}